The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / A New Role for Lateral Flow in Cancer Diagnosis
Oncology Point of care testing Molecular Pathology

A New Role for Lateral Flow in Cancer Diagnosis

A quantitative colorimetric assay distinguished patients with PDAC from healthy controls

11/19/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: A New Role for Lateral Flow in Cancer Diagnosis

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: A New Role for Lateral Flow in Cancer Diagnosis
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingEarly clinical evaluation of a potential portable assay; the source describes testing closer to the patient as a possible future use, and routine diagnostic use has not been established.

Key Highlights

  • A sandwich ELISA using the selected immunoreagents showed a linear sAXL response and a reported limit of detection of 0.16 ng/mL.
  • The lateral flow assay detected higher sAXL concentrations in the PDAC group and statistically differentiated patients from healthy controls.
  • Lateral flow measurements were compared with ELISA findings to provide a reference for quantitative results.
  • The study was small and did not assess discrimination from chronic pancreatitis, benign pancreatic disease, other cancers, or inflammatory conditions.
  • The findings do not establish the assay for screening or as a replacement for imaging, histopathology, cytology, or laboratory ELISA.

Guideline-Based Recommendations

Diagnosis

  • Imaging, tissue sampling, and histopathologic assessment remain central to PDAC diagnosis.
  • The lateral flow sAXL assay is an investigational potential aid and has not been validated for routine diagnosis.

Management

  • Do not treat the assay as a replacement for imaging, histopathology, cytology, or laboratory ELISA.
  • The article does not establish the assay for population screening or definitive primary diagnosis.

Monitoring & Follow-up

  • CA 19-9 analysis is used mainly to support disease monitoring rather than population screening or definitive primary diagnosis.
  • The article does not report a clinical monitoring role for the lateral flow sAXL assay.

Risks

  • The evaluation included only 20 patients with PDAC and 20 healthy controls.
  • Performance against chronic pancreatitis, benign pancreatic disease, other cancers, and inflammatory conditions was not tested.
  • Reference intervals, clinical cutoffs, sensitivity, specificity, and performance across disease stages remain to be established.

Patient & Prescribing Data

Plasma samples from 20 patients with PDAC and 20 healthy controls in a Barcelona-Hospital del Mar cohort.

No treatment was evaluated. The assay is a diagnostic research tool, and the study does not establish clinical prescribing or routine diagnostic use.

Clinical Best Practices

  • Interpret the reported group difference in sAXL in light of the small cohort and healthy-control-only comparison.
  • Do not use the study findings to infer performance in differential diagnosis or screening.
  • Further larger, independent, multicenter studies are needed to establish reference intervals, cutoffs, sensitivity, specificity, and performance across disease stages and relevant differential diagnoses.

Related Resources & Content

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.